Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HSV-1 G207 |
Synonyms | |
Therapy Description |
HSV-1 G207 is an oncolytic herpes simplex virus-1 (HSV-1), which may lead to antitumor activity, including cytotoxicity and inhibition of angiogenesis and tumor growth (PMID: 15720798, PMID: 30918335). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HSV-1 G207 | G207|Oncolytic HSV-1 G207|HSV-1-G207|HSV-1G207 | HSV-1 G207 is an oncolytic herpes simplex virus-1 (HSV-1), which may lead to antitumor activity, including cytotoxicity and inhibition of angiogenesis and tumor growth (PMID: 15720798, PMID: 30918335). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03911388 | Phase I | HSV-1 G207 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | Active, not recruiting | USA | 0 |
NCT04482933 | Phase II | HSV-1 G207 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Recruiting | USA | 0 |